Boggi U, Mosca F, Vistoli F, Signori S, Del Chiaro M, Bartolo T Vanadia, Amorese G, Coppelli A, Marchetti P, Mariotti R, Rondinini L, Del Prato S, Rizzo G
Department of Surgery and Transplantation, University of Pisa, Pisa, Italy.
Transplant Proc. 2005 Mar;37(2):1274-7. doi: 10.1016/j.transproceed.2005.01.024.
Portal-enteric drainage (PED) might be particularly suitable for pancreas transplantation alone (PTA), since it has been associated with an immunologic advantage and achieves excellent metabolic results. We describe our experience with a consecutive series of 40 PTAs with PED.
Between April 2001 and March 2004, 40 consecutive PTAs were performed with PED. Recipients were selected according to the American Diabetic Association recommendations. Donors were selected according to standard criteria irrespective of HLA match, although matching for A and B loci was considered at the time of graft allocation. Immunosuppression consisted of induction treatment with basiliximab (n = 34) or thymoglobulin (n = 6), and maintenance therapy with steroids, mycophenolate mofetil, and tacrolimus.
After a mean cold ischemia time of 690 minutes (range, 517-965 min) all pancreases functioned immediately. Three grafts were lost due to hyperacute or accelerated rejection. No graft was lost to vascular thrombosis, although 5 (12.5%) nonocclusive thromboses were identified and the grafts were rescued with intravenous heparin infusion. A repeat laparotomy was required in 7 recipients (17.5%) No patient required multiple repeat laparotomies, and none died. After a mean follow-up of 16.4 months (range, 1-36 mo), 2 recipients were diagnosed with rejection episodes, which were reversed with steroid boluses. Actuarial 3-year patient, and graft survival rates were 100% and 94.9%, respectively. The following parameters showed significant improvement compared with pretransplantation evaluation: hemoglobin A1C concentration, total and high-density lipoprotein cholesterol levels, arterial blood pressure, cardiac performance, retinopathy, proteinuria, and neuropathy.
Pancreas transplantation alone with PED provides high rates of long-term insulin-independence.
门静脉-肠道引流术(PED)可能特别适用于单纯胰腺移植(PTA),因为它具有免疫优势并能取得出色的代谢结果。我们描述了连续40例采用PED的PTA的经验。
2001年4月至2004年3月,连续进行了40例采用PED的PTA。根据美国糖尿病协会的建议选择受者。供者根据标准标准选择,不考虑HLA配型,尽管在分配移植物时考虑了A和B位点的配型。免疫抑制包括用巴利昔单抗(n = 34)或抗胸腺细胞球蛋白(n = 6)进行诱导治疗,以及用类固醇、霉酚酸酯和他克莫司进行维持治疗。
平均冷缺血时间为690分钟(范围517 - 965分钟)后,所有胰腺立即发挥功能。3例移植物因超急性或加速排斥反应而丢失。没有移植物因血管血栓形成而丢失,尽管发现了5例(12.5%)非闭塞性血栓形成,通过静脉输注肝素挽救了移植物。7例受者(17.5%)需要再次剖腹手术。没有患者需要多次再次剖腹手术,也没有患者死亡。平均随访16.4个月(范围1 - 36个月)后,2例受者被诊断为排斥反应发作,通过大剂量类固醇治疗得以逆转。3年的患者和移植物存活率分别为100%和94.9%。与移植前评估相比,以下参数有显著改善:糖化血红蛋白浓度、总胆固醇和高密度脂蛋白胆固醇水平、动脉血压、心脏功能、视网膜病变、蛋白尿和神经病变。
采用PED的单纯胰腺移植可实现高比例的长期胰岛素非依赖。